Takara Bio Inc. provided earnings guidance for the six months ending September 30, 2021 and full year ending March 31, 2022. For the six months, the company expected net sales of ¥29,700, operating profit of ¥11,400 million, net income attributable to owners of parent of ¥7,900 million or ¥65.61 per share. For the year, the company expected net sales of ¥54,200, operating profit of ¥17,000 million, net income attributable to owners of parent of ¥11,900 million or ¥98.82 per share.